NATURE | A new study suggests that the entry of low-cost generic antibiotics onto the market in the US does not drive higher consumption of these antibiotics. Drug resistance is a global public health challenge that contributes to mortality from infectious diseases and increases healthcare costs. Antibiotic use is a primary driver of resistance and is at a high level in the United States. As much as 30 per cent of oral antibiotic use in the US may be unnecessary. This study, written by leading drug-resistance experts in Europe and the US, including Boston University law professor and CARB-X Executive Director Kevin Outterson, suggests that more research is needed to explore the effect of generic entry on antibiotic prices and to consider differences among antibiotic classes. Research is also needed to determine the effects, including access and antibiotic resistance, when generics enter the market in low- and middle-income countries